Literature DB >> 27559186

Minocycline: Rheumatoid Arthritis.

Theresa McEvoy.   

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

Entities:  

Year:  2016        PMID： 27559186      PMCID： PMC4981101          DOI： 10.1310/hpj5107-535

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  9 in total

1.  Extensive pigmentation secondary to minocycline treatment of rheumatoid arthritis.

Authors:  S A Assad; E F Bernstein; B Brod; W D James
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

2.  Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) Trial.

Authors:  G B Bluhm; J T Sharp; B C Tilley; G S Alarcon; S M Cooper; S R Pillemer; D O Clegg; S P Heyse; D E Trentham; R Neuner; D A Kaplan; J C Leisen; L Buckley; H Duncan; M Tuttleman; S Li; S E Fowler
Journal:  J Rheumatol       Date:  1997-07       Impact factor: 4.666

3.  Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine.

Authors:  J R O'Dell; K W Blakely; J A Mallek; P J Eckhoff; R D Leff; S J Wees; K M Sems; A M Fernandez; W R Palmer; L W Klassen; G A Paulsen; C E Haire; G F Moore
Journal:  Arthritis Rheum       Date:  2001-10

4.  Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial.

Authors:  J R O'Dell; C E Haire; W Palmer; W Drymalski; S Wees; K Blakely; M Churchill; P J Eckhoff; A Weaver; D Doud; N Erikson; F Dietz; R Olson; P Maloley; L W Klassen; G F Moore
Journal:  Arthritis Rheum       Date:  1997-05

5.  Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial.

Authors:  M Kloppenburg; F C Breedveld; J P Terwiel; C Mallee; B A Dijkmans
Journal:  Arthritis Rheum       Date:  1994-05

6.  Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.

Authors:  B C Tilley; G S Alarcón; S P Heyse; D E Trentham; R Neuner; D A Kaplan; D O Clegg; J C Leisen; L Buckley; S M Cooper; H Duncan; S R Pillemer; M Tuttleman; S E Fowler
Journal:  Ann Intern Med       Date:  1995-01-15       Impact factor: 25.391

7.  Minocycline-induced hyperpigmentation in rheumatoid arthritis.

Authors:  Brian T Fay; Annemarie P Whiddon; Susan Puumala; Natalie A Black; James R O'Dell; Ted R Mikuls
Journal:  J Clin Rheumatol       Date:  2008-02       Impact factor: 3.517

Review 8.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

9.  Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.

Authors:  Millicent Stone; Paul R Fortin; Cesar Pacheco-Tena; Robert D Inman
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666
  9 in total
  3 in total

1.  Effects of crystalline penicillin G sodium on human T-cells differentiation.

Authors:  Ali Shams; Amir Abdian Asl; Sina Owlia; Mohammad Bagher Owlia
Journal:  J Res Med Sci       Date:  2021-02-27       Impact factor: 1.852

2.  Anti-inflammatory effects of minocycline are mediated by retinoid signaling.

Authors:  Vera Clemens; Francesca Regen; Nathalie Le Bret; Isabella Heuser; Julian Hellmann-Regen
Journal:  BMC Neurosci       Date:  2018-09-21       Impact factor: 3.288

3.  Opinion: An Existing Drug to Assess In Vivo for Potential Adjunctive Therapy of Ebola Virus Disease and Post-Ebola Syndrome.

Authors:  Katherine Hendricks; Meredith Gilman Parrado; John Bradley
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.